STATE-OF-THE-ART REVIEW

Genetic approaches to understand cellular responses to oxygen availability

Brian M. Ortmann and James A. Nathan

Department of Medicine, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, UK

Keywords
genetic screens; hypoxia; hypoxia inducible factor; oxygen; VHL

Correspondence
J. A. Nathan, Department of Medicine, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK
E-mail: jan33@cam.ac.uk

(Received 8 March 2021, revised 24 May 2021, accepted 14 June 2021)
doi:10.1111/febs.16072

Oxygen-sensing mechanisms have evolved to allow organisms to respond and adapt to oxygen availability. In metazoa, oxygen-sensing is predominantly mediated by the hypoxia inducible factors (HIFs). These transcription factors are stabilised when oxygen is limiting, activating genes involved in angiogenesis, cell growth, pH regulation and metabolism to reset cell function and adapt to the cellular environment. However, the recognition that other cellular pathways and enzymes can also respond to changes in oxygen abundance provides further complexity. Dissecting this interplay of oxygen-sensing mechanisms has been a key research goal. Here, we review how genetic approaches have contributed to our knowledge of oxygen-sensing pathways which to date have been predominantly focused on the HIF pathway. We discuss how genetic studies have advanced the field and outline the implications and limitations of such approaches for the development of therapies targeting oxygen-sensing mechanisms in human disease.

Introduction

The ability to sense and respond to oxygen levels is common to most organisms. While the pathways involved may differ, they all serve to maintain cell survival when oxygen is scarce, as well as drive biological processes dependent on oxygen gradients. Therefore, dissecting how cells respond to oxygen has been at the forefront of biological research. This review focuses on how genetic studies have contributed to our understanding of oxygen-sensing mechanisms.

In metazoa, hypoxia inducible factors (HIFs) are the well-established core components of responses to oxygen levels [1–6]. These transcription factors are constitutively expressed but their protein levels are regulated according to oxygen availability in a post-translational manner. When oxygen is present, the HIF-α subunit (HIF-1α or HIF-2α) of the HIF dimeric complex is hydroxylated at two conserved proline residues by one of three prolyl hydroxylases (PHDs, or EGLNs), which act as the recruitment signal for the Von-Hippel Lindau (VHL) E3 ligase that ubiquitinates HIF-α, facilitating its rapid proteasome-mediated degradation. In oxygen limiting conditions, the PHDs have been at the forefront of biological research. This review focuses on how genetic studies have contributed to our understanding of oxygen-sensing mechanisms.

In metazoa, hypoxia inducible factors (HIFs) are the well-established core components of responses to oxygen levels [1–6]. These transcription factors are constitutively expressed but their protein levels are regulated according to oxygen availability in a post-translational manner. When oxygen is present, the HIF-α subunit (HIF-1α or HIF-2α) of the HIF dimeric complex is hydroxylated at two conserved proline residues by one of three prolyl hydroxylases (PHDs, or EGLNs), which act as the recruitment signal for the Von-Hippel Lindau (VHL) E3 ligase that ubiquitinates HIF-α, facilitating its rapid proteasome-mediated degradation. In oxygen limiting conditions, the PHDs are no longer catalytically active, and the HIF-α subunit is no longer hydroxylated. This stabilises HIF-α, allowing its binding to HIF1β (also known as Aryl Hydrocarbon Receptor Nuclear Translocator, ARNT)

Abbreviations
2-OG DD, 2-oxoglutarate-dependent dioxygenase; 2-OG, 2-oxoglutarate; ccRCC, clear cell renal cell carcinoma; CRISPR, clustered regularly interspaced short palindromic repeats; FH, fumarate hydratase; FIH-1, factor inhibiting HIF-1; HIF, hypoxia inducible factor; OGDHC, 2-oxoglutarate dehydrogenase complex; PHD, prolyl hydroxylase; SDH, succinate dehydrogenase; TCA, tricarboxylic acid; VHL, Von-Hippel Lindau.
to form a heterodimeric transcription factor which activates hundreds of genes involved in angiogenesis, metabolism, pH, inflammation and cell growth.

Prolyl hydroxylases are members of the 2-oxoglutarate (2-OG) dependent dioxygenase (2-OG DD) family and provide the oxygen-sensing component of the HIF pathway [7]. There are approximately 60 of these enzymes in humans, which all require oxygen, iron and the rate-limiting tricarboxylic acid (TCA) cycle metabolite 2-OG (Fig. 1). Whether all members of the 2-oxoglutarate DD family have the capacity to act as oxygen sensors depends on their binding affinity for oxygen, and in many cases, the affinities are not known. However, other 2-OG DDs are involved in modulating HIF transcriptional activity, aside from the PHDs. Factor Inhibiting HIF-1, (FIH-1) is an asparagine hydroxylase of the 2-OG DD family that remains catalytically active at lower oxygen concentrations than PHDs, and modulates transcriptional activation of a subset of HIF target genes [8,9]. 2-OG DDs are also involved in controlling histone demethylation and DNA hydroxymethylcytosine modifications, both of which have also been shown to be oxygen sensitive [10–12] (Fig. 1).

While 2-OG DDs highlight the ability of some oxygen-dependent enzymes to sense cellular oxygen, other sensing mechanisms have also been uncovered. Rapid oxygen-sensing in the carotid body relies on a distinct mechanism to the HIF pathway, with acute hypoxia leading to cell depolarisation, calcium influx and neurotransmitter release [13]. How oxygen is actually sensed in these cells is still debated. Oxygen-sensitive potassium channels were thought to mediate the calcium influx, but loss or inhibition of the main potassium channels in rodents does not prevent the response of glomus cells to hypoxia [14]. It is most likely that oxygen-sensing is linked to activity of the mitochondrial respiratory chain and reactive oxygen species (ROS) generation [15], although how ROS signals to the membrane channels remains to be resolved.

The evolution of distinct oxygen-sensing mechanisms in plants [16] and fission yeast [17], as well as the identification of oxygen-sensing cysteine dioxygenases in mammals [18] provides further complexity to how cells adapt and respond to oxygen availability. Dissecting the cellular mechanisms involved and relative contribution of these pathways to oxygen-sensing is challenging, but has been aided by genetic studies, particularly with respect to the HIF response. Here, we summarise the genetics of the HIF pathway, consider the contributions that forward and reverse genetics have made to the field, and outline where genetic approaches may be of benefit in understanding other cellular responses.

**Fig. 1.** 2-Oxoglutarate-dependent dioxygenases regulate diverse cellular functions. 2-OG DDs can sense and adapt to cellular availability of oxygen, iron and 2-OG. These enzymes have diverse roles, including (a) DNA/RNA demethylation (e.g. AlkBH enzymes and FTO), (b) DNA hydroxymethylation (TETs), (c) Histone demethylation (KDMs), (d) HIF-α stability (PHDs) and transcriptional activation of gene targets (FIH-1), and (e) collagen prolyl hydroxylation (CPH enzymes).
to oxygen. We also discuss advances in genome editing techniques, the merits of and potential pitfalls of genetic screens, and their implications for future studies on cellular oxygen-sensing.

**Evolutionary, molecular and clinical genetics in oxygen-sensing pathways**

**Von Hippel Lindau disease and HIFs**

The VHL E3 ligase is named from its identification as the gene mutated and inactivated in VHL disease [19]. This autosomal dominant familial syndrome is characterised by the development of renal cell carcinomas, pheochromocytomas and angiogenic tumours [20] (Table 1). Tumours do not typically develop until adulthood, and renal cell cancers and cerebral haemangioblastomas are major causes of morbidity [21]. The tumour suppressor nature of VHL is supported by the finding that nearly 90% of clear cell renal cell carcinomas (ccRCCs) have loss of VHL function [22]. The trajectory of VHL loss in these sporadic renal cell cancers is fascinating, whereby recent multi-region genomic profiling of primary tumours has mapped their clonal evolution [23]. VHL mutations are clearly the most significant drivers in renal cell cancer, but these clonal mutations can occur early in life and take several decades to lead to the formation of tumours (median 28 years) [23]. The addition of one or more other driver mutations (e.g. BAP1, SETD2, PBRM1 or PTEN) reduces the time from identification of the clonal ancestor to tumour diagnosis to 2–5 years [23].

Tumours in VHL disease are hypervascular and associated with increased red cell production, and it was observed that VHL deficiency led to the induction of genes activated in hypoxia, such as VEGF [24,25]. These observations suggested that VHL may be regulating the then recently identified HIFs by the Semenza group [26,27]. Work pioneered by the Kaelin and Ratcliffe groups subsequently demonstrated that VHL was an E3 ligase and responsible for the ubiquitination and proteasome-mediated degradation of HIF-α [28–31].

**Phenotypic genetic analysis of oxygen-sensing in metazoans: from prolyl hydroxylation to erythrocytosis**

Biochemical assays of VHL in association with HIF-α subunits demonstrated that prolyl hydroxylation must be enzymatic and defined the oxygen-sensitive domains of HIF-1α and HIF-2α [32]. However, the genes involved were not identified. HIF-1α orthologues had been identified in worms (Caenorhabditis elegans) [32], which

| Gene | Mutations | Associated tumours | HIF activation | Epigenetic changes |
|------|-----------|--------------------|----------------|-------------------|
| VHL | VHL deletion (Gene inactivation), (Promotor hypermethylation) [22] | ccRCC, pheochromocytomas, haemangioblastomas | Yes (predominantly HIF-2α) | Histone and DNA methylation |
| SDHB | C213T STOP, 221insCAG, C270G, G436A, T708C, G721A, 847delTCTCC (frameshift), C859A, C881A, P131R, M71fsX80 [49–51] | Paragangliomas, pheochromocytomas, renal cell carcinomas (rare) | Yes | DNA methylation |
| SDHC | R133T [46,47,49] | Paragangliomas, pheochromocytomas | Yes | DNA methylation |
| SDHD | H102L, P81L, N92Y, G14A STOP, C33A STOP, C112T STOP, G274T, C361T STOP, R38X, Q109X, L128fsC134 [45–49] | Paragangliomas, pheochromocytomas | Yes | DNA methylation |
| FH | A117P, T381I, A194T, N329S [48,57,58] | Paragangliomas, pheochromocytomas, leiomyomas, renal cell carcinomas | Yes | Histone and DNA methylation |
| IDH | R132H (IDH1) | Glioblastoma, acute myeloid leukaemia | No | Histone and DNA methylation |
| OGDHc (DLST) | R132H (IDH1) R132C (IDH1) R140Q (IDH2) R172K (IDH2) [61–65] | Paragangliomas, pheochromocytomas | No (accumulation of D-2-HG) | DNA methylation |

Table 1. Genetic mutations associated with the HIF pathway and tumour formation. Summary of known mutations in genes associated with HIF activation and cancer syndromes. Associated epigenetic mutations that may arise from impaired 2-OG DD activity by KDMs and TETs also indicated.
displayed the same sensitivity to oxygen concentrations as observed in humans. The ability of worms to be easily genetically manipulated provided the ideal tool to define the enzymes involved. Epstein et al. [33] first examined the main 2-OG DDs known at that time, the collagen PHDs, but these had no effect on HIF stability. They then analysed the worms for other potential hydroxylases, identifying that Egl-9 showed all the structural requirements for 2-OG DD activity. The presence of a single Egl-9 gene (analogous to PHD2) in worms and flies accounted for the regulation of HIF. However, there has been an expansion in this group of enzymes in mammals, with humans encoding three PHD genes. PHD2 accounts for the main hydroxylase regulating HIFs in most human cells, but all the enzymes are involved, and have been implicated in regulating HIFs and other substrates in different conditions [7,34].

Since the initial characterisation of the HIF pathway in C. elegans, this organism and other less diverse metazoans have continued to provide a useful tool to understand the HIF response. Worms are viable without hif-1, vhl and egl-9, and this has enabled analysis of genes regulated by HIF-1, as well as phenotypic studies into the role of the HIF pathway in ageing [35]. The HIF response is also well conserved in Drosophila melanogaster, with Similar (Sim) and Tango (Tgo) bHLH-PAS proteins forming an analogous HIF-1α/HIFβ heterodimer [36,37]. The ease of genetic manipulation in Drosophila has helped map the interactions of HIF with target of rapamycin (TOR) pathways [38], and the effects on cell growth [39]. In addition, gene silencing screens in Drosophila have helped identify co-activators recruited by HIF-1 for selective gene transcription, which we discuss in more detail (see Activation of the HIF response).

The identification of the HIF pathway has also provided the basis for exploring the genetic causes of erythrocytosis (also known as polycythemia). HIF regulation of EPO transcription prompted studies to understand congenital erythrocytosis. Chuvash polycythemia is a rare autosomal recessive condition endemic in the Russian region of Chuvashia. Ang et al. [40] mapped the locus to a missense mutation in VHL (Arg200Trp) which impaired VHL ubiquitination of HIF-α and enhanced activation of HIF target genes. Studies indicate that this mutation arose from a single ancestor around 12 000 years ago, explaining the occurrence of this mutation occurring in other populations via migration [41]. However, the Chuvash mutation does not lead to a tumour syndrome, and this likely relates to the residual activity of VHL that occurs, which is absent in VHL disease.

Other mutations in VHL have been linked to erythrocytosis, as have many mutations in PHD2 and some in HIF-2α (reviewed by Lee and Percy [42]). While a detailed discussion of the mutations is beyond the scope of this review, it is worth noting that mutations in VHL, PHD2 and HIF-2α have discrete phenotypes, present in different age groups and are distinct from VHL disease. Moreover, how these monogenetic disorders relate to populations living at high altitude has been of interest. A genome-wide association study of those living in the Tibetan plateau versus the lowland Han identified single nucleotide polymorphisms (SNPs) in HIF-2α resulting in lower haemoglobin levels [43]. The potential advantage of these SNPs is not fully understood and may relate to reducing mountain sickness or relate to a role of HIF-2α in foetal development [43,44].

**Hereditary cancer syndromes provide links between mitochondrial metabolism and oxygen-sensing**

Aside from VHL disease, rarer hereditary cancer syndromes have provided insights into the HIF pathway. Familial mutations in two TCA enzymes, succinate dehydrogenase (SDH) and fumarate hydratase (FH) result in cancer syndromes that include the development of renal cell carcinomas, as well as several other tumours (e.g. paragangliomas, phaeochromocytomas with SDH and leiomyomas with FH) [45-48] (Table 1). The activation of genes regulated by HIFs and the vascular nature of these tumours prompted studies exploring whether metabolites may alter PHD activity, potentially independently of HIFs [47].

Germline SDH mutations in subunits -B, -C and -D all give rise to paragangliomas and phaeochromocytomas [49,50], with SDHB being rarely linked to renal cell cancers [51]. It was hypothesised that the accumulation in succinate would impair PHD activity, and consequently shown in SDHD depleted immortalised cell lines that HIF-α prolyl hydroxylation was reduced, resulting in HIF stabilisation and activation of HIF target genes [52]. Biochemical and structural studies subsequently confirmed that TCA cycle intermediates, and fumarate in particular, could competitively inhibit PHDs and other 2-OG DDs [53]. However, the relative importance of HIF in driving the SDH mutant tumours is still debated, as ROS have been implicated [54], and succinate accumulation will also impair TET driven 5-hmc of DNA [55], which by altering DNA demethylation, may also be a major driver of the tumour development [56].
A similar picture has been noted with FH familial tumours [57,58]. Here, FH mutations can again lead to HIF activation through the accumulation of fumarate and PHD inhibition. Fumarate is in fact a more potent inhibitor of PHD activity than succinate [53]. However, it should not be concluded that HIF activation is solely responsible for tumour formation, and the current paradigm involves metabolic adaptation with reductive carboxylation, epigenetic modifications and haem biosynthesis, along with a contribution by HIF transcriptional programming [59,60].

Aside from these familial cancer syndromes, there is considerable evidence that somatic mutations in TCA enzymes drive other tumours and modulate oxygen-sensitive enzymes. Isocitrate dehydrogenase (IDH) catalyses the formation of 2-OG from isocitrate, and driver somatic mutations in IDH (e.g. IDH-1 R132H) have been identified in glioblastomas and acute myeloid leukaemia (Table 1). These mutations alter enzyme function to produce the D enantiomer of 2-hydroxylutarate (D-2-HG). This metabolite inhibits a number of 2-OG DDs, particularly KDMs and TETs [61,62], contributing to tumour formation by altering the epigenetic landscape [63–65]. However, HIF stabilisation is not observed, and D-2-HG can actually potentiate HIF degradation, although the mechanism involved is debated [64–66].

While hereditary cancer syndromes have informed the identification of key components of the HIF pathway, reciprocal, cell-based genetic screens have helped identify genes responsible for germline cancers with unclear aetiology. For example, the identification that mutations in a further key component on the TCA cycle, the 2-oxoglutarate dehydrogenase complex (OGDHc), lead to recurrent paragangliomas and pheochromocytomas [67], arose from observations with a forward genetic screen uncovering that OGDHc loss causes L enantiomer accumulation of 2-HG [68] (Table 1) (see also Genetic screening section).

Evolutionary genetics and comparative biology define other oxygen-sensing mechanisms

While the HIF pathway is conserved in metazoans, distinct oxygen-sensing mechanisms exist in yeast and plants. Understanding how oxygen is sensed in these organisms has not only uncovered interesting biology, but helped define other oxygen-sensing pathways that occur in humans, alongside the HIF response.

Fission yeast (Schizosaccharomyces pombe) have an intriguing system that relies on the sterol sensing pathway, which involves several oxygen-dependent steps. The SREBP orthologue, Sre1 is a transcription factor that is unusually retained in the ER when cholesterol is present, but on cholesterol depletion is cleaved, allowing the release of an N terminal fragment that translocates to the nucleus (Sre1N). In S. pombe, Sre1N also stimulates the transcription of genes required for hypoxic adaptation [39]. Hughes et al. showed that Sre1N is stabilised when oxygen levels are low, and is degraded by the proteasome. Remarkably, this oxygen-sensitivity is also regulated by a 2-OG DD, termed Ofd1 [69]. However, an analogous combined steroid and oxygen-sensing pathway has not been identified in higher metazoans. Although three mammalian orthologues of Ofd1 exist (OGFOD1–3), they do not seem to regulate the mammalian orthologue of Sre1, SREBP2, and are instead involved in ribosomal hydroxylation (OGFOD1) [70].

In plants, oxygen-sensing is governed by ubiquitin enzymes of the N-end rule pathway [16,71]. A family of cysteine oxidases act as oxygen sensors and control hypoxic adaptation through modification and subsequent degradation of target proteins through the Cysbranch of the N-degron pathway [16,71]. This work led Masson et al. [18] to investigate the mechanism of N terminal cysteine oxidation in mammals. They identified a thiol oxidase, ADO, as a cysteine oxidase involved in the N-end rule pathway. ADO catalyses cysteine to cysteine sulfenic acid in an oxygen-sensitive manner, regulating the ubiquitination and degradation of N-end rule substrates in G-protein signalling and calcium signalling. This comparative biological approach highlights that other oxygen-sensing pathways have evolved in mammals aside from HIF, and understanding how they provide a co-ordinated response to changes in oxygen will be important to address in future studies.

**Genetic screening approaches to interrogate the HIF pathway and adaption to oxygen availability**

In considering how genetic approaches have been applied to oxygen-sensing pathways, it is helpful to outline the techniques involved, and the relative merits and disadvantages of different systems. Firstly, it is important to acknowledge that genetic screens in organisms such as worms, fungi and flies have provided scientific advances for around the past 100 years [33,72,73]. However, genetic screens in mammalian cells have been more challenging, principally due to genetic complexity and manipulation of ploidy. One approach to circumvent the issue of ploidy was to find haploid or near-haploid cell lines for use in genetic screens. Chinese hamster ovary (CHO) cells are near-haploid, and early
studies of the HIF pathway demonstrated the utility of chemical mutagenesis in CHO cells to help define HIF-1 dependent and independent gene expression in hypoxia [74]. A further breakthrough in performing knockout based screens in haploid human cells arose from pioneering studies by the Brummelkamp group, where they established the use of haploid (HAP1) or the near-haploid (KBM7) cells derived from a patient with chronic myeloid leukaemia (CML) to carry out unbiased genetic screening [75–77]. These insertional gene-trap mutagenesis screens have been extensively used to identify host–pathogen restriction factors [75,76], as well as being applied to transcriptional regulation [78] and the HIF response [68].

RNA interference (RNAi) and CRISPR (clustered regularly interspaced short palindromic repeats)-Cas mutagenesis have provided the other major methodological advances to facilitate genetic screens. Both have been transformative in allowing genetic screens to be conducted in mammalian cells, and the rapid reduction in protein levels with RNAi is advantageous for genome-wide screens [79]. However, a potential limitation of RNAi is the reasonably high level of off-target effects and difficulty in achieving complete genome coverage. CRISPR-Cas gene editing typically has less off-target effects than RNAi, and the ability to target nucleotide sequences with high efficiency allows pooled sgRNA screens to be conducted rapidly. The most commonly used strategy involves pooled libraries of between 4 and 10 sgRNAs targeting all genes within the genome, and transducing these sgRNA into cells expressing the Cas9 nuclease, resulting in insertion-deletions (indels) and loss of gene function. Fusion of a catalytically inactive Cas9 with either a transcriptional repressor (CRISPR interference, CRISPRi) or transcriptional activator (CRISPR activation, CRISPRa) provides further versatility to the CRISPR sgRNA approach [80,81]. While the advantages of CRISPR-Cas screens are clear, there are several limitations that should be considered. Off-target mutations can still occur and CRISPR-Cas mutagenesis is in principle binary, such that mutations will result in complete loss of gene function, which is less evident than with siRNA depletion. In addition, indel formation typically results in loss of gene function after several days, with phenotypes taking longer to develop, and the potential for confounding cellular adaptation to occur. However, given the flexibility of CRISPR-Cas nuclease systems to cut DNA in distinct manners and even target RNA [82], we will continue to see rapid advances in these screening strategies.

**VHL and synthetic lethality**

One of the first areas to take advantage of genetic screening approaches was the search for genes that would be synthetically lethal in combination with VHL mutations (Fig. 2). 90% of renal cell carcinomas have VHL mutations [83], and identifying genes or molecules that are synthetically lethal with VHL could offer major therapeutic advantages, as recently demonstrated with the combination of PARP inhibition in tumours defective in BRCA1/2 [84–86].

Screening approaches for synthetic lethality with VHL loss have typically used chemical inhibition and RNAi in renal cell carcinoma cells (e.g. RCC4 or 786-O cells). A number of potential targets and compounds have been identified, but there is generally low concordance between the studies. For instance, Turcotte et al. [87] screened VHL-deficient and VHL-reconstituted RCC4 cells with a 64 000 drug compound library and identified that STF-62247 selectively killed the VHL-deficient cells. Cell death was HIF independent and thought to be mediated by STF-62247 accumulation in lysosomes and inhibition of late stage autophagy [88]. Thompson et al. [89] also used RCC4 cells and screened with a library of pharmacologically active compounds. They identified Rho-associated coiled-coil containing protein kinase (ROCK) as a potential synthetic lethal target [89]. Treatment with ROCK inhibitors reduced cell proliferation, migration, and induced cell death in VHL-deficient cells, presumably in a Rho-dependent manner. ROCK inhibition can alter also autophagy [90], and it is possible that autophagy is involved in this synthetic-lethal interaction, as observed with STF-62247. However, this has not yet been experimentally addressed.

Rather than using a chemical library, Bommi-Reddy et al. [91] used a kinase focused short-hairpin RNA (shRNA) library in 786-O and RCC4 cells, identifying a dependence on CDK6, MER and MAP2K1 activity. Loss of viability following CDK6 and MAP2K1 depletion was independent of HIF, consistent with VHL having additional roles outside of the hypoxia response pathway [92,93]. CDK4/6 small molecule inhibition also decreased the viability of VHL null cells, and these studies have been replicated using an siRNA screen in Drosophila that was coupled with a targeted inhibitor library screen in renal cancer cell lines [94]. CDK4/6 inhibition may be a therapeutically tractable strategy in renal cancer, as in combination therapy with the HIF-2α inhibitor, PT2399, CDK4/6 inhibition produced a synergistic suppression of cell viability [95].
Targeted shRNA libraries have also been used to examine depletion of histone and chromatin modifiers in a range of VHL-deficient renal cancer cell lines [96]. VHL loss was associated with increased H3K27 acetylation and monomethylation, and synthetic lethality was observed with depletion of the H3K27 methyltransferase EZH1 [96]. Interestingly, H3K27me1 can be removed by the demethylases KDM6A and KDM6B [11,97] which are both transcriptionally regulated by hypoxia, and function as ccRCC repressors [98]. It is thought that KDM6A is already downregulated in renal cancer cells, contributing to their hypersensitive EZH1 H3K27 methyltransferase activity [96]. The screen also identified another demethylase KDM4A, which demethylates the H3K36 mark, as a potential synthetic lethal partner of VHL loss [99,100]. Although this has not been experimentally validated, it is speculated that this may counteract the loss of the H3K36 SETD2 methyltransferase, which is frequently lost in renal cancers [101].

Renal cancer cell lines have proved valuable in studying VHL genetic interactions, but may not be truly representative of tumours in vivo, where growth is also influenced by the microenvironment and immune surveillance. Wolff et al. [102] sought to create a more representative in vivo setting by coculturing VHL-deficient and VHL-proficient cells and using a ~12 800 small molecules library. Their high throughput imaging screening method identified homoharringtonine (HHT), an FDA-approved drug used in the treatment of chronic myeloid leukaemia, as a synthetic lethal partner of VHL loss, although mechanistically it is not understood what mediates this interaction [102]. Moreover, this co-culturing approach does not fully recapitulate tumorigenesis, and there is still a need to establish studies that more...
faithfully capture the growth of renal tumours in a clinical context. One such approach may be to apply in vivo CRISPR mutagenesis [103,104] to renal cell tumours, and it will be of interest to understand how these approaches inform on the role of recapitulating the tumour microenvironment.

Lastly, complementary computational methods have been used to screen for synthetic lethality with VHL loss [105–107]. One computational approach, termed DAISY (data mining synthetic lethality identification pipeline), based on the assumption that synthetically lethal interactions can be identified by pairs of genes whose co-inactivation in tumours occurs much less than expected by chance alone, identified several candidate genes that may be synthetically lethal with VHL loss, including EZH1 [106]. They did not identify CDK4/6 or other targets identified in experimental screens. Overall, it remains unclear why there is considerable variation in the targets/compounds identified in the different screening approaches, but it likely depends on the methodologies used and differences in the cell lines. CDK4/6 and EZH1 are the most promising targets, but there may still be other synthetically lethal interactions to be uncovered.

Regulation of HIF stability

Genetic screens have been helpful in delineating pathways that can influence HIF stability. Prior to the advent of KBM7 near-haploid human cells, Vaux et al. [108] took advantage of the near-haploid nature of CHO cells, to mutagenise cells expressing HRE-linked cell surface markers, and screen for increased HRE activity. Clones that demonstrated increased cell surface expression also showed increased HIF-1α levels. However, this was not due to mutations in HIF-1α itself, but predominantly arose due to VHL mutagenesis and impaired ubiquitination. Two clones showed increased HIF-1α protein levels that were not due to VHL mutations, indicating that other pathways that influence HIF-α stability were still to be found.

Bemis et al. [109] took a complementary approach and used a retroviral cDNA library in U-251 glioblastoma cells expressing an HRE driving GFP to find genes involved in aerobic activation of HIF-α. They found a COP9 signalosome (CSN) component, CSN5, activated HIF-1α in aerobic conditions. CSN5 bound the C terminal ODD in HIF-1α, reducing prolyl hydroxylation and stabilising HIF-1α. This study and those undertaken in CHO cells [108] highlight the dominance of the PHD-VHL axis, but still raise the question that other signals may be involved in HIF-α stability.

Rather than expressing a cDNA library, we applied genome-wide mutagenesis screens to near-haploid human cells expressing a dynamic HIF-α reporter [68,110,111]. This approach was initially applied to KBM7 cells using the retroviral gene-trapping mutagenesis strategy developed by Brummelkamp and others [75,77]. We generated KBM7 cells stably expressing a HIF GFP reporter, consisting of an HRE(3x) driving GFP fused to the ODD of HIF-1α, and following mutagenesis with the gene-trapping retrovirus, used flow cytometry to sort and enrich for cells that showed high GFP levels in aerobic conditions. By mapping the insertion sites of the gene-trapping retrovirus, we identified several pathways and genes involved in HIF-1α stability, independent of oxygen availability. Four main pathways were identified: (a) The canonical PHD-VHL axis, (b) intracellular iron metabolism, (c) mTOR and (d) 2-OG metabolism [68,111] (Fig. 2). An unexpected finding was that mutations in the OGDHc, a rate-limiting step in the TCA that converts 2-OG to succinyl CoA, was critical in regulating HIF levels in aerobic conditions. Loss of OGDHc activity led to stabilisation of HIF in a nonprolyl hydroxylated form, which is counterintuitive, as 2-OG levels were increased. However, we uncovered that 2-OG accumulation and reductive metabolism drives the formation of L enantiomer of 2-HG (L-2-HG), which inhibited PHD catalytic function [68]. In addition to the control of HIF-1α levels, L-2-HG also had a significant effect on the activity of the TET enzymes in control of DNA methylation. We hypothesised that the consequences of impaired PHD and TET activity following OGDHc mutations may be analogous to other TCA enzyme mutations, and predispose to tumour formation. This indeed proved to be the case and subsequent to our studies Remacha et al. [67] identified that human germline mutations in one of the OGDHc subunits, DLST, led to recurrent pheochromocytomas and paragangliomas, placing the OGDHc alongside SDH and FH in hereditary cancer syndromes that involved aerobic activation of HIFs (Table 1).

In addition to uncovering a role for OGDHc, the near-haploid genetic approach identified a role for mitochondrial lipoylation in the HIF response. Lipoylation is an essential post-translational fatty acid modification for several mitochondrial enzymes, including the OGDHc, where it undergoes cyclical oxidation and reduction on DLST to form an intermediate with the succinyl moiety. Mutations in lipoic acid synthase (LIAS) were highly enriched in the mutagenesis screen. We found that LIAS loss decreased OGDHc activity, and thereby led to L-2HG formation and PHD inhibition [68]. Interestingly, we also observed HIF-1α...
stabilisation in fibroblasts from patients with germline mutations in lipoic acid synthesis genes. These individuals present with severe neurological disease in early childhood (a form of Leigh syndrome), and it is possible that HIF-α activation here may be beneficial in relation to this form of mitochondrial disease, but this requires further investigation.

A further area in which our genetic approach has been helpful is in understanding the role of the vacuolar H+ATPase (V-ATPase) in HIF-α stability. Prior studies had identified that V-ATPase inhibition resulted in increased HIF-1α levels, suggesting that HIFs could be a substrate for lysosomal degradation [112]. However, it was unclear under what conditions this would occur, as the degradation of HIF through VHL-mediated ubiquitination is dominant. The mutagenesis screen confirmed that V-ATPase loss can lead to activation of the HIF response, as a number of V-ATPase subunits were enriched for gene-trap insertions [111]. In addition, two uncharacterised genes were identified (CCDC115 and TMEM199), and we subsequently showed these to be required for V-ATPase activity [111]. However, we did not observe lysosomal degradation of HIF-1α. Instead, we found that PHD activity was inhibited when the V-ATPase was not active, and this was due to intracellular iron depletion, highlighting the involvement of the endosomal-lysosomal pathway for cellular iron metabolism, and how this links with the HIF pathway.

More recently, we have used genome-wide CRISPR-Cas9 mutagenesis to complement the near-haploid screens [110]. These genome-wide pooled libraries are equivalent to the gene-trapping method in uncovering the main pathways involved in HIF stability and have also provided additional insights by delineating the function of previously uncharacterised genes. The putative mitochondrial gene ABHD11 was highly enriched for sgRNAs following genome-wide CRISPR-Cas9 mutagenesis. Given the propensity of the screens to identify components of 2-OG metabolism, we hypothesised that ABHD11 may regulate 2-OG abundance. We observed that ABHD11 associates with the OGDH complex and is required for basal OGDHc activity. Interestingly, ABHD11 was required to maintain functional lipoylation and redox cycling of the OGDHc [110]. The physiological role of ABHD11 is not yet known, but it is intriguing that an enzyme involved in redox regulation of the TCA cycle interfaces with the HIF oxygen-sensitive pathway.

A remaining question that has not been fully answered is whether there is a requirement for other ubiquitin ligases or DUBs in HIF-α protein stability. Bett et al. [113] used a ‘ubiquitome’ siRNA library to identify ubiquitin enzymes involved in HIF stability, conducting the screen in 1% oxygen rather than aerobic conditions. They identified that USP52 (ubiquitin-specific protease 52)/PAN2 (poly(A) nuclease 2) depletion decreased HIF-luciferase reporter levels. Interestingly, USP52 is likely to be a ‘pseudo-DUB’ without isopeptidase activity, and they went on to show an involvement of USP52 in maintaining HIF-1α mRNA stability in cytoplasmic P-bodies. While these findings did not show a direct involvement of deubiquitination, other studies suggest that DUBs are involved in HIF regulation. Bremm et al. [114] took a focused approach to explore the role of Otubain DUBs in HIF-1α regulation and used siRNA-mediated depletion to screen for their effect on a HRE-luciferase reporter in hypoxia. Cezanne (OTUD7B) was found to be involved in HIF-1α degradation, but in a VHL and PHD independent manner. Subsequent studies identified that Cezanne altered HIF-2α expression, which was dependent on E2F1 [115]. The detailed mechanisms of how Cezanne controls HIFs remains to be fully understood, but these studies highlight that DUBs involved in HIF regulation may occur at both the translation and post-translational level.

**Activation of the HIF response**

Genetic screens to find determinants of HIF-α stability have informed on the involvement of metabolic and other cellular pathways in the HIF response. A distinct query relates to how HIFs activate a transcription response once stabilised. Both HIF-1α and HIF-2α can bind to the same HRE, but chromatin immunoprecipitation sequencing (ChIP-seq) experiments demonstrate that these isoforms can occupy distinct loci within the genome. This raises the question of how HIF isoforms target gene selectively?

We and others have applied genetic approaches to understand activation of the HIF response and the interaction of HIFs with chromatin (Fig. 2). The Wappler group performed an unbiased genome-wide screen using an RNAi library using *D. melanogaster* cells expressing a HIF-specific reporter [73]. Cells were treated with the iron chelator (DFO) to inhibit PHD function and activate HIF activity, and cells that failed to activate HIF activity were selected. Around 30 genes were identified, which included previously identified components of the CSN [109], miTOR and the phosphoinositide 3-kinase (PI3K) pathway. They also identified an essential role for miRNA system in the regulation of *Sim* mRNA, dependent on *Agoante 1* (Ago1) [73]. Subsequent studies have identified around 40 miRNAs that can regulate HIF-α/HIFβ expression...
directly or indirectly, reflecting the complex nature of RNA silencing [116]. A number of chromatin remodelers were also identified in the D. melanogaster siRNA screen, including components of the SWI/SNF complex [73]. Kenneth et al. [117] have consequently shown that the SWI/SNF complex can alter HIF-1α mRNA expression. The involvement of SWI/SNF is likely to be more complicated though, as several components of the complex are frequently mutated in renal cell tumours (e.g. PBRM1) [22], where HIF levels are increased.

Transcription factor binding and gene transcription are ultimately controlled by chromatin accessibility and epigenetic modifications. One of the primary mechanisms through which chromatin accessibility is controlled is through N terminal post-translational modification of histone tails, where lysine acetylation and methylation can help regulate gene activation and repression. Early work in the hypoxia field demonstrated the role of CBP/p300, an acetyltransferase and epigenetic modifications. One of the primary components of the complex are frequently mutated in renal cells that failed to accumulate a fluorescent signal in cell tumours (e.g. PBRM1) [22], where HIF levels are increased.

Essentiality and viability screens in oxygen limiting conditions

Essentiality or ‘cell fitness’ screens have recently attempted to shed light on how other cellular processes promote survival when oxygen is scarce. Jain et al. [122] performed genome-wide CRISPR growth screens at 21%, 5% and 1% oxygen, to determine essential genes dependent on oxygen availability. They identified ~ 200 essential genes in high oxygen and ~ 100 genes in low oxygen conditions.Canonical HIF pathway genes were not detected as essential, with VHL loss only showing a growth defect in 21% oxygen. The reasons for these findings are not entirely clear, but may relate to differences in growth of the cancer cell line used (K562, lymphoblast cells), and the requirement for HIFs in an in vivo setting, where consequences of HIF activation, such as promoting angiogenesis, will be more apparent. Cells in low oxygen instead relied on lipid metabolism, with genes involved in peroxisomes being essential. Supplementation with unsaturated fatty acids (oleic acid) restored cell growth, but this essentiality phenotype was only observed in HEK293T and K562 cells. Therefore, it is likely that hypoxia cell fitness genes differ between cell types and tissues, and the relative importance of such variations remains to be determined.

In contrast to the reliance on lipid metabolism in hypoxia, most fitness genes in a high oxygen setting were mitochondrial, with Complex I components particularly evident as essential in 21% oxygen but not 1% oxygen [122]. These findings complement prior studies by the Mootha group whereby they used a genome-wide CRISPR Cas9 genetic screen to identify genes that could suppress a model of mitochondrial disease (Complex III inhibition) with VHL being the top hit [123]. Using a variety of genetic and chemical tools, Jain et al. [123] showed that hypoxia was protective in preventing cell death in a zebrafish and a mouse model
of mitochondrial disease (Ndufs4 KO, Complex I deficiency). This survival benefit is not due to HIF activation, which failed to improve brain disease in the Ndufs4 null mice, but is thought to arise from neuronal oxygen toxicity that occurs when the respiratory chain is disrupted [124].

These cell fitness screens highlight the relationship between oxygen availability and mitochondrial function, but several questions remain. Why cell types differ in genes that are essential are not yet clear, and how noncancer cells behave when oxygen is limiting is not known. It is not straightforward to distinguish between genes that alter cellular oxygen levels (e.g. oxygen consumption) in these fitness screens versus those that are due to changes in oxygen-sensing. Combining essentiality screens with mitochondrial or HIF reporters may overcome some of these challenges.

**Conclusion and future directions**

Over the past 20 years genetic studies, advances in gene editing and phenotypic screening approaches have contributed to our understanding of how cells respond to oxygen. Most studies have been focused on the HIF pathway, and despite the central involvement of VHL-mediated ubiquitination of HIF-α, other components of the ubiquitin machinery remain to be fully determined. This may relate to certain pathways and genes being preferentially selected in HIF phenotypic screens, with loss of VHL or PHD activity always being identified across multiple cell types, or redundancy within the ubiquitin system. Whilst the detection of VHL and PHDs serve as useful controls in screens, their preferential selection may conceal other genes or signals that have intermediate effects on HIF stability/activity. Designing focused sgRNA libraries excluding genes already known to regulate HIF may help overcome the preferential selection of VHL and PHD loss. Alternatively, supplementation with PHD co-factors (e.g. iron or 2-OG) may help avoid bias towards particular cell pathways.

The ability to now undertake gene editing in any cell type should allow genetic screens to move away from cancer cell lines to primary cells and to explore oxygen-sensing in specialist cell types. For example, it is now theoretically possible to interrogate the rapid oxygen-sensing in the glomus cells of the carotid body using CRISPR-Cas systems and potentially determine the relative contribution of the respiratory electron transport chain and ROS generation to the membrane depolarisation.

Lastly, advances in CRISPR-Cas technology are likely to overcome some of the existing limitations: (a) Lethal phenotypes in mutagenesis screens can be potentially avoided with CRISPRi and CRISPRa approaches, (b) in vivo CRISPR-Cas screens may allow a more detailed understanding of cell autonomous and nonautonomous phenotypes, (c) genetic redundancy is still an obstacle, but combinatorial CRISPR screens have been developed, where co-disruption of gene function leads to decreased cell fitness [125], and (d) CRISPR-Cas9 knock-ins will help inform on endogenous gene regulation, without the need for overexpressed or surrogate reporter systems. Combining these technological advances with complementary genetic data from population human studies [126] will provide further insights into the complexity of oxygen-sensing pathways and open up new therapeutic avenues to explore.

**Acknowledgements**

We thank the members of the Nathan group for their helpful comments on the manuscript. This work was supported by a Wellcome Senior Clinical Research Fellowship to JAN (215477/Z/19/Z), and a Lister Institute Research Fellowship to JAN. This work was also supported by the NIHR Cambridge Biomedical Research Centre and the Addenbrooke’s Charitable Trust.

**Conflict of interest**

The authors declare no conflict of interest.

**Author contributions**

JAN and BMO conceptualised the review, wrote and edited the manuscript. JAN was responsible for funding acquisition.

**References**

1. Kaelin WG Jr & Ratcliffe PJ (2008) Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. *Mol Cell* **30**, 393–402.
2. Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. *Cell* **148**, 399–408.
3. Pugh CW & Ratcliffe PJ (2017) New horizons in hypoxia signaling pathways. *Exp Cell Res* **356**, 116–121.
4. Wilson JW, Shakir D, Batie M, Frost M & Rocha S (2020) Oxygen-sensing mechanisms in cells. *FEBS J* **287**, 3888–3906.
5. Palazon A, Goldrath AW, Nizet V & Johnson RS (2014) HIF transcription factors, inflammation, and immunity. *Immunity* **41**, 518–528.
6 Lee P, Chandel NS & Simon MC (2020) Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. *Nat Rev Mol Cell Biol* **21**, 268–283.

7 Islam MS, Leising TM, Chowdhury R, Hopkinson RJ & Schofield CJ (2018) 2-Oxoglutarate-dependent dioxygenases. *Ann Rev Biochem* **87**, 585–620.

8 Mahon PC, Hirota K & Semenza GL (2001) FIH-1: a novel protein that interacts with HIF-α and VHL to mediate repression of HIF-1 transcriptional activity. *Genes Dev* **15**, 2675–2686.

9 Hewitson KS, McNeill LA, Riordan MV, Tian Y-M, Bullock AN, Welford RW, Elkins JM, Oldham NJ, Bhattacharya S, Gleadle JM et al. (2002) Hypoxia-inducible factor (HIF) asparaginyl hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. *J Biol Chem* **277**, 26351–26355.

10 Thienpon B, Steinbacher J, Zhao H, D’Anna F, Arias-Mayenco I, González-Barneo J et al. (2005) SREBP masson N, Keeley TP, Giuntoli B, White MD, Puerta ML, Perata P, Hopkinson RJ, Flashman E, Licausi F & Ratcliffe PJ (2019) Conserved N-terminal cysteine dioxygenases transduce responses to hypoxia in animals and plants. *Science* **365**, 65–69.

11 Maher ER & Kaelin WG Jr (1997) von Hippel-Lindau disease. *Medicine* **76**, 381–391.

12 Latif F, Torny K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. *Science* **260**, 1317–1320.

13 Maher ER, Yates JR & Ferguson-Smith MA (1990) Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. *J Med Genet* **27**, 311–314.

14 Cancer Genome Atlas Research Network (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature* **499**, 43–49.

15 Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, O’Brien T, Lopez JI, Watkins TBK, Nicol D et al. (2018) Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. *Cell* **173**, 595–610.e11.

16 Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, Oldfield EH, Klausner RD & Linehan WM (1996) Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. *Proc Natl Acad Sci USA* **93**, 10589–10594.

17 Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr & Goldberg MA (1996) Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. *Proc Natl Acad Sci USA* **93**, 10595–10599.

18 Semenza GL, Nejfelt MK, Chi SM & Antonarakis SE (1991) Hypoxia-inducible nuclear factors bind to an enhancer element located 3’ to the human erythropoietin gene. *Proc Natl Acad Sci USA* **88**, 5680–5684.

19 Wang GL, Jiang BH, Rue EA & Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. *Proc Natl Acad Sci USA* **92**, 5510–5514.

20 Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER & Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature* **399**, 271–275.

21 Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V & Kaelin WG (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. *Nat Cell Biol* **2**, 423–427.

22 Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS & Kaelin WG Jr (2001) HIFalpha targeted for VHL-mediated
Genetic approaches and oxygen-sensing

B. M. Ortmann and J. A. Nathan

31 Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468–472.

32 Jiang H, Guo R & Powell-Coffman JA (2017) The EGLN-HIF O2-sensing system: multiple inputs and feedbacks. Mol Cell 66, 772–779.

33 Mehta R, Mehta R, Steinkraus KA, Sutphin GL, Ramos FJ, Ivan M & Kaelin WG Jr (2017) The EGLN-HIF O2-sensing protein that is required for adaptation to hypoxia. Proc Natl Acad Sci USA 98, 7916–7921.

34 Ivan M & Kaelin WG Jr (2017) The EGLN-HIF O2-sensing system: multiple inputs and feedbacks. Mol Cell 66, 772–779.

35 Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR, Metzen E, Wilson MI, Dhandh K, et al. (2001) The O2 sensing PAS protein similar. Science 292, 107–109.

36 Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR, Metzen E, Wilson MI, Dhandh K, et al. (2001) The EGLN-HIF 2, a human homolog of the C. elegans Egl-9 PAS protein that is required for adaptation to hypoxia. Proc Natl Acad Sci USA 98, 7916–7921.

37 Bacon NC, Wappner P, O’Rourke J, Bartlett SM, Bacon NC, Wappner P, O’Rourke J, Bartlett SM, et al. (2002) Control of the hypoxic response in Drosophila melanogaster by the basic helix-loop-helix PAS protein similar. Mol Cell Biol 22, 6842–6853.

38 Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, von der Mey A, Taschner PE, Rubinski WS, Myers EN et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287, 848–851.

39 Frei C & Edgar BA (2004) Drosophila cyclin D/Cdk4 requires Hif-1 prolyl hydroxylation to drive cell growth. Dev Cell 6, 241–251.

40 Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, Liu E, Sergueeva AI, Miasnikova GY, Mole D et al. (2002) Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32, 614–621.

41 Liu E, Percy MJ, Amos CI, Guan Y, Shete S, Stockton DW, McMullin MF, Polyakova LA, Ang SO, Pastore YD et al. (2004) The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. Blood 103, 1937–1940.

42 Lee FS & Percy MJ (2011) The HIF pathway and erythrocytosis. Annu Rev Pathol 6, 165–192.

43 Beall CM, Cavalleri GL, Deng L, Elston RC, Gao Y, Knight J, Li C, Li JC, Liang Y, McCormack M et al. (2010) Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci USA 107, 11459–11464.

44 Beall CM (2007) Two routes to functional adaptation: Tibetan and Andean high-altitude natives. Proc Natl Acad Sci USA 104 (Suppl 1), 8655–8660.

45 Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, von der Mey A, Taschner PE, Rubinski WS, Myers EN et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287, 848–851.

46 Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K et al. (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346, 1459–1466.

47 Pollard P, Wortham N & Tomlinson I (2003) The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase. Ann Med 35, 634–635.

48 Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamplum H, Rahman S et al. (2002) Germline mutations in FH predispose to dominantly inherited ureteric fibroids, skin leiomyomatosis and papillary renal cell cancer. Nat Genet 30, 406–410.

49 Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdić CM, Savul SA, McLeod DR, Yee HA, Brackmann DE, Slattery WH III, Myers EN et al. (2002) Prevalence of SDHB, SDHC, and SDHD germline mutations in clinical patients with head and neck paragangliomas. J Med Genet 39, 178–183.

50 Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Sköldberg F, Husebye ES, Eng C & Maher ER (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69, 49–54.

51 Morris MR, Maino E, Morgan NV, Gentle D, Astuti D, Moch H, Kishida T, Yao M, Schraml P, Richards FM et al. (2004) Molecular genetic analysis of FH1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. J Clin Pathol 57, 706–711.

52 >Selak MA, Armour SM, MacKenzie ED, Boulaibeh H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB & Gottlieb E (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylation. Cancer Cell 7, 77–85.
Genetic approaches and oxygen-sensing

53 Hewitson KS, Lienard BM, McDonough MA, Clifton IJ, Butler D, Soares AS, Oldham NJ, McNeill LA & Schofield CJ (2007) Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem 282, 3293–3301.

54 Guzy R, Sharma B, Bell E, Chandel N & Schmacker P (2008) Loss of the SdhB, but not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol 28, 718–731.

55 Laukka T, Mariani CJ, Ihantola T, Cao JZ, Hokkanen K, Kaelin WG Jr, Godley LA & Koivunen P (2016) Fumarate and succinate regulate expression of hypoxia-inducible genes via TET enzymes. J Biol Chem 291, 4256–4265.

56 Morin A, Gonçalves J, Moog S, Castro-Vega LJ, Job S, Buffet A, Fontenille MJ, Woszczycz J, Gimenez-Roqueplo AP, Letouzet E et al. (2020) TET-mediated hypermyelination primes SDH-deficient cells for HIF2α-driven mesenchymal transition. Cell Rep 30, 4551–4566.e7.

57 Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J et al. (2005) HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate hydratase in development and activation of the hypoxia pathway. Cancer Cell 8, 143–153.

58 Pollard PJ, Spencer-Dene B, Shukla D, Howarth K, Nye E, El-Bahrawy M, Deheragoda M, Joannou M, McDonald S, Martin A et al. (2007) Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell 11, 311–319.

59 Schmidt C, Sciaccovelli M & Frezza C (2020) Fumarate hydratase in cancer: a multifaceted tumour suppressor. Semin Cell Dev Biol 98, 15–25.

60 Sciaccovelli M, Gonçalves E, Johnson TI, Zecchin VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo SR, Tran MG et al. (2016) Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature 537, 544–547.

61 Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT et al. (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-keto glutarate-dependent dioxygenases. Cancer Cell 19, 17–30.

62 Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Li XS, Woon EC, Yang M et al. (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12, 463–469.

63 Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A et al. (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474–478.

64 Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkisson S, Losman JA, Joensuu P, Bergmann U, Gross S et al. (2012) Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483, 484–488.

65 Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley GS, Root DE, Ebert BL & Kaelin WG Jr (2013) (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621–1625.

66 Tarhonskaya H, Rydzik AM, Leung IK, Loik ND, Chan MC, Kawamura A, McCullagh JS, Claridge TD, Flashman E & Schofield CJ (2014) Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. Nat Commun 5, 3423.

67 Remacha L, Pirman D, Mahoney CE, Coloma J, Calsina B, Curras-Freixes M, Leton R, Torres-Perez R, Richter S, Pita G et al. (2019) Recurrent germline DLST mutations in individuals with multiple pheochromocytomas and paragangliomas. Am J Hum Genet 104, 651–664.

68 Burr SP, Costa AS, Grice GL, Timms RT, Lobb IT, Freisinger P, Dodd RB, Dougan G, Lehner PJ, Frezza C et al. (2016) Mitochondrial protein lipoylation and the 2-oxoglutarate dehydrogenase complex controls HIF1alpha stability in aerobic conditions. Cell Metab 24, 740–752.

69 Hughes BT & Espenshade PJ (2008) Oxygen-regulated degradation of fission yeast SREBP by Fdh1, a prolyl hydroxylase family member. EMBO J 27, 1491–1501.

70 Loenarz C, Sekirnik R, Thalhammer A, Ge W, Spivakovsky E, Mackeen MM, McDonough MA, Cockman ME, Kessler BM, Ratcliffe PJ et al. (2014) Hydroxylation of the eukaryotic ribosomal decoding center affects translational accuracy. Proc Natl Acad Sci USA 111, 4019–4024.

71 Gibbs DJ, Lee SC, Isa NM, Granuglia S, Fukao T, Bassel GW, Correia CS, Corbineau F, Theodoulou FL, Bailey-Serres J et al. (2011) Homeostatic response to hypoxia is regulated by the N-end rule pathway in plants. Nature 479, 415–418.

72 Korn M, Schmidpeter J, Dahl M, Müller S, Voll LM & Koch C (2015) A genetic screen for pathogenicity genes in the hemibiotrophic fungus Colletotrichum higginsianum identifies the plasma membrane proton pump Pma2 required for host penetration. PLoS One 10, e0125960.

73 Dekany A, Romero NM, Bertolin AP, Thomas MG, Leishman CC, Perez-Perrin JI, Boccaccio GL & Wappner P (2010) Drosophila genome-wide RNAi
screen identifies multiple regulators of HIF-dependent transcription in hypoxia. *PLoS Genet* **6**, e1000994.

74 Wood SM, Wiesener MS, Yeates KM, Okada N, Pugh CW, Maxwell PH & Ratcliffe PJ (1998) Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 alpha-subunit (HIF-1alpha). Characterization of hif-1alpha-dependent and -independent hypoxia-inducible gene expression. *J Biol Chem* **273**, 8360–8368.

75 Carette JE, Guimaraes CP, Varadarajan M, Park AS, Wueitrich I, Godarova A, Kotecki M, Cochran BH, Spooner E, Ploegh HL et al. (2009) Haploid genetic screens in human cells identify host factors used by pathogens. *Science* **326**, 1231–1235.

76 Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch et al. (2011) Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. *Nature* **477**, 340–343.

77 Carette JE, Guimaraes CP, Wueitrich I, Blomen VA, Varadarajan M, Sun C, Bell G, Yuan B, Mueller MK, Nijman SM et al. (2011) Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. *Nat Biotechnol* **29**, 542–546.

78 Tchasovnikarova IA, Timms RT, Matheson NJ, Wals K, Antrobus R, Göttingen B, Dougan G, Dawson MA & Lehner PJ (2015) GENE SILENCING. Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells. *Science* **348**, 1481–1485.

79 Mohr SE, Smith JA, Shamu CE, Neumüller RA & Perrimon N (2014) RNAi screening comes of age: improved techniques and complementary approaches. *Nat Rev Mol Cell Biol* **15**, 591–600.

80 Larson MH, Gilbert LA, Wang X, Lim WA, Weissman JS & Qi LS (2013) CRISPR interference (CRISPRi) for sequence-specific control of gene expression. *Nat Protoc* **8**, 2180–2196.

81 Lau E (2014) Genetic screens: CRISPR screening from both ways. *Nat Rev Genet* **15**, 778–779.

82 Shivram H, Cress BF, Knott GJ & Doudna JA (2021) Controlling and enhancing CRISPR systems. *Nat Chem Biol* **17**, 10–19.

83 Cho H, Du X, Rizzi JP, Liberzon E, Chakraborty AA, Gao W, Carvo I, Signoretti S, Bruick RK, Josey JA et al. (2016) On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. *Nature* **539**, 107–111.

84 Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ & Hellday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* **434**, 913–917.

85 Evers B, Hellday T & Jonkers J (2010) Targeting homologous recombination repair defects in cancer. *Trends Pharmacol Sci* **31**, 372–380.

86 Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* **434**, 917–921.

87 Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA & Giaccia AJ (2008) A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. *Cancer Cell* **14**, 90–102.

88 Bouhamdani N, Comeau D, Cormier K & Turcotte S (2019) STF-62247 accumulates in lysosomes and blocks late stages of autophagy to selectively target von Hippel-Lindau-inactivated cells. *Am J Physiol Cell Physiol* **316**, C605–C620.

89 Thompson JM, Nguyen QH, Singh M, Pavesic MW, Nesterenko I, Nelson LJ, Liao AC & Razorenova OV (2017) Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma. *Oncogene* **36**, 1080–1089.

90 Gurkar AU, Chu K, Raj L, Bouley R, Lee SH, Kim YB, Dunn SE, Mandinova A & Lee SW (2013) Identification of ROCK1 kinase as a critical regulator of Beclin1-mediated autophagy during metabolic stress. *Nat Commun* **4**, 2189.

91 Bommi-Reddy A, Almeciga I, Sawyer J, Geisen C, Li W, Harlow E, Kaelin WG Jr & Grueneberg DA (2008) Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. *Proc Natl Acad Sci USA* **105**, 16484–16489.

92 Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X et al. (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. *Science* **361**, 290–295.

93 Hasanov E, Chen G, Chowdhury P, Weldon J, Ding Z, Jonasch E, Sen S, Walker CL & Dere R (2017) Ubiquitation and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL. *Oncogene* **36**, 3450–3463.

94 Nicholson HE, Tariq Z, Housden BE, Jennings RB, Stransky LA, Perrimon N, Signoretti S & Kaelin WG Jr (2019) HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species. *Sci Signal* **12**, eaay0482.

95 Gordan JD, Bertout JA, Hu CJ, Diehl JA & Simon MC (2007) HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. *Cancer Cell* **14**, 335–347.

96 Chakraborty AA, Nakamura E, Qi J, Creech A, Jaffe JD, Paulk J, Novak JS, Nagulapalli K, McBrayer SK, Cowley GS et al. (2017) HIF activation causes synthetic lethality between the VHL tumor suppressor...
and the EZH1 histone methyltransferase. *Sci Transl Med* 9, eaa5527.

97 Cribs AP, Terlecki-Zaniewicz S, Philpott M, Baardman J, Ahern D, Lindow M, Obad S, Oerum H, Sampey B, Mander PK *et al.* (2020) Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism. *Proc Natl Acad Sci USA* 117, 6056–6066.

98 Guo X, Tian Z, Wang X, Pan S, Huang W, Shen Y, Gui Y, Duan X & Cai Z (2015) Regulation of histone demethylase KDM6B by hypoxia-inducible factor-2α. *Acta Biochim Biophys Sin (Shanghai)* 47, 106–113.

99 Black JC, Manning AL, Van Rechem C, Kim J, Ladd S, Cho J, Pineda CM, Murphy N, Daniels DL, Montagna C *et al.* (2013) KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. *Cell* 154, 541–555.

100 Pfister SX, Ahrabi S, Zalmas LP, Sarkar S, Ayamard F, Bachrati CZ, Helleday T, Legube G, La Thangue NB, Porter AC *et al.* (2014) SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. *Cell Rep* 7, 2006–2018.

101 González-Rodríguez P, Engskog-Vlachos P, Zhang H, Murgoci AN, Zerres I & Joseph B (2020) SETD2 mutation in renal clear cell carcinoma suppresses autophagy via regulation of ATG12. *Cell Death Dis* 11, 69.

102 Wolff NC, Pavia-Jiménez A, Tcheuyap VT, Alexander S, Vishwanath M, Christie A, Xie XJ, Williams NS, Kapur P, Posner B *et al.* (2015) High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau tumor suppressor. *Nat Med* 21, 1209–1219.

103 Perez-Perri JI, Dengler VL, Audetat KA, Pandey A, Bonner EA, Urh M, Mendez J, Daniels DL, Wappner P, Galbraith MD *et al.* (2016) The TIP60 complex is a conserved coactivator of HIF1A. *Cell Rep* 16, 37–47.
120 Galbraith MD, Allen MA, Bensard CL, Wang X, Schwinn MK, Qin B, Long HW, Daniels DL, Hahn WC, Dowell RD et al. (2013) HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. *Cell* **153**, 1327–1339.

121 Ortmann BM, Burrows N, Lobb IT, Arnaiz E, Wit N, Bailey PSJ, Jordon L, Lombardi O, Peñalver A, McCaffrey J et al. (2021) The HIF complex recruits the histone methyltransferase SET1B to activate specific hypoxia-inducible genes. *Nat Genet*.

122 Jain IH, Calvo SE, Markhard AL, Skinner OS, Tolstunov TL, Ast T & Mootha VK (2020) Genetic screen for cell fitness in high or low oxygen highlights mitochondrial and lipid metabolism. *Cell* **181**, 716–727.e11.

123 Jain IH, Zazzeron L, Goli R, Alexa K, Schatzman-Bone S, Dhillon H, Goldberger O, Peng J, Shalem O, Sanjana NE et al. (2016) Hypoxia as a therapy for mitochondrial disease. *Science* **352**, 54–61.

124 Jain IH, Zazzeron L, Goldberger O, Marutani E, Wojtkiewicz GR, Ast T, Wang H, Schleifer G, Stepanova A, Brepoels K et al. (2019) Leigh syndrome mouse model can be rescued by interventions that normalize brain hyperoxia, but not HIF activation. *Cell Metab* **30**, 824–832.e3.

125 Thompson NA, Ranzani M, van der Weyden L, Iyer V, Offord V, Droop A, Behan F, Gonçalves E, Speak A, Iorio F et al. (2021) Combinatorial CRISPR screen identifies fitness effects of gene paralogues. *Nat Commun* **12**, 1302.

126 Mark C, Jim D, Martin D, Leila E, Tom F, Sue H, Tim H, Luke J, Nick M, Jeanna M-P et al. (2019) The National Genomics Research and Healthcare Knowledgebase. v5.1, Genomics England, UK.